Clinical Trials Browser

Interventional × Stomach Neoplasms × zimberelimab × Clear all

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05329766 2026-04-29

EDGE-Gastric

Phase 2 Active not recruiting

332 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT05891171 2026-03-31

ARC-25

Phase 1 Active not recruiting

40 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

STAR-221

EDGE-Gastric

ARC-25

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

ARC-12